Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What is the Projected CAGR for the Carcinoid Tumor Market Size from 2025 to 2034?
In recent times, the market size for carcinoid tumors has seen an accelerated pace of growth. A rise from $1.61 billion in 2024 to $1.78 billion in 2025, with a compound annual growth rate (CAGR) of 10.7%, is expected. The historical growth is credited to an increase in neuroendocrine tumor cases, heightened awareness of uncommon cancers, enhancements in healthcare facilities, access to targeted therapies, and the broadening scope of clinical trials for innovative treatment options.
Expectations for the carcinoid tumor market size are high, with substantial growth predicted over the coming years. A forecasted growth to $2.65 billion by 2029, with a compound annual growth rate (CAGR) of 10.5%, is anticipated. The significant growth predicted for this forecast period can be linked to the burgeoning demand for personalized medicine, continued emphasis on early detection and diagnosis, the rising preference for minimally invasive surgeries, broadening research into new therapies, and an increasing application of molecular targeted therapies. Noteworthy trends projected in the forecast period encompass the incorporation of AI and machine learning in diagnostic procedures, a move towards combined therapies, the use of telemedicine and remote monitoring, a focus on patient-centered care, and cooperative research efforts.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21127&type=smp
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Carcinoid Tumor Market?
The expansion of the carcinoid tumor market is projected to be fueled by the increasing number of individuals with obesity. This group comprises those whose body mass index (BMI) surpasses the 30 mark, suggestive of high body fat levels. Numerous factors have contributed to the rise in obesity, including unhealthy eating patterns, absence of physical exercise, sedentary routines, and greater intake of processed foods rich in calories. The role of obesity in carcinoid tumor formation is linked to its tendency to encourage sustained inflammation, insulin insensitivity, and elevated production of growth stimulants that foster tumor expansion. For example, the Centers for Disease Control and Prevention, a government agency based in the United States, noted in September 2023 that in 2022, the adult obesity rate was reported to be 35% or more in 22 states, an increase from 19 states the previous year. As a result, the escalating obese populace plays a key role in fueling the expansion of the carcinoid tumor market.
Which Key Market Segments Comprise the Carcinoid Tumor Market and Drive Its Revenue Growth?
The carcinoid tumor market covered in this report is segmented –
1) By Disease Type: Gastrointestinal Neuroendocrine Tumor, Pancreatic Neuroendocrine Tumor, Lung Neuroendocrine Tumor, Other Disease Types
2) By Treatment: Octreotide, Lanreotide, Telotristat ethyl, Capecitabine (Xeloda), 5-Fluorouracil (5-FU), Doxorubicin (Adriamycin), Etoposide (VP-16), Dacarbazine (DTIC), Streptozocin, Other Treatments
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Online Channel, Offline Channel
5) By End User: Hospital And Clinics, Academic Institutions, Research Organizations
Subsegments:
1) By Gastrointestinal Neuroendocrine Tumor: Small Bowel Neuroendocrine Tumors, Colorectal Neuroendocrine Tumors, Appendiceal Neuroendocrine Tumors
2) By Pancreatic Neuroendocrine Tumor: Insulinoma, Non-insulinoma, Glucagonoma
3) By Lung Neuroendocrine Tumor: Typical Carcinoid Tumors, Atypical Carcinoid Tumors
4) By Other Disease Types: Thymic Neuroendocrine Tumors, Ovarian Neuroendocrine Tumors
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21127&type=smp
Which Areas Are Leading Regions in the Carcinoid Tumor Market Expansion Across the Globe?
North America was the largest region in the carcinoid tumor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carcinoid tumor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Key Market Trends in theCarcinoid Tumor Market Over the Coming Years?
The primary players within the carcinoid tumor market are honing in on advancements in diagnostic technology, particularly the fully automated test for chromogranin A, with the aim of improving early detection and patient treatment results. The automated chromogranin A (CgA) test serves as an essential diagnostic instrument that accurately measures chromogranin A levels, a biomarker typically linked to neuroendocrine and carcinoid tumors. For example, in October 2023, Thermo Fisher Scientific Inc., a renowned American biotechnology research company, procured FDA endorsement for its Thermo Scientific B·R·A·H·M·S CgA II KRYPTOR immunoassay. This is hailed as the first FDA-sanctioned Chromogranin A (CgA) test and so far, the only automated immunoassay worldwide employed for tracking tumor progression in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET). The designed assay utilized to measure CgA concentration in human serum enables labs and cancer centers to monitor tumor growth and determine treatment effectiveness. The replacement of manual laboratory constructed tests with this escalates lab productivity and provides a more straightforward result interpretation. The test functions using the Thermo Scientific B·R·A·H·M·S KRYPTOR compact PLUS random-access immunoassay analyzer, which employs TRACE technology to produce accurate outcomes in less than 30 minutes.
View the full report here:
https://www.thebusinessresearchcompany.com/report/carcinoid-tumor-global-market-report
How Is the Carcinoid Tumor Market Conceptually Defined?
A carcinoid tumor is a rare, slow-growing type of neuroendocrine tumor that typically arises in the gastrointestinal tract or lungs. It originates from enterochromaffin cells, which produce and release hormones such as serotonin. Symptoms may vary depending on the tumor’s location and whether it secretes hormones, potentially causing carcinoid syndrome.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21127
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
